CFDE Data Portal | Search LINC02817

	Label	Description
	LINC02817 Gene (Entity type)	ENSG00000234754 - long intergenic non-protein coding RNA 2817
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE155031 catechin SH-SY5Y 5 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE155031 catechin SH-SY5Y 6 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE155031 catechin SH-SY5Y 6 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE148200 gemcitabine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE203329 HCC knockout 0 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE182680 GSE182683 dexamethasone 0 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE155031 catechin SH-SY5Y 5 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS

LINC02817

ENSG00000234754 - long intergenic non-protein coding RNA 2817

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human up

A Gene Set from LINCS

GSE155031 catechin SH-SY5Y 5 v 3 human up

A Gene Set from LINCS

GSE155031 catechin SH-SY5Y 6 v 0 human up

A Gene Set from LINCS

GSE155031 catechin SH-SY5Y 6 v 3 human up

A Gene Set from LINCS

GSE148200 gemcitabine 1 v 2 human up

A Gene Set from LINCS

GSE203329 HCC knockout 0 v 3 human dn

A Gene Set from LINCS

GSE182680 GSE182683 dexamethasone 0 v 4 human up

A Gene Set from LINCS

GSE155031 catechin SH-SY5Y 5 v 2 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.